Presenilin-1 (PS1) deficiency in neurons derived from knockout mice results in a marked reduction in the production of amyloid peptide ␤A4 and an accumulation of carboxyterminal fragments of the amyloid precursor protein (APP).
The biochemical process that leads to Alzheimer's disease (AD) pathology is not yet fully understood. The two major pathological hallmarks of the disease are tangles and amyloid plaques. The relationship between these lesions remains unclear. While the cause(s) of the sporadic form(s) of the disease are unknown, several mutations in genes that cause the familial form of the disease (FAD) have been identified. [1] [2] [3] Since the pathology of the genetic forms is identical to that observed in the sporadic forms, it is our working hypothesis that a common pathogenetic pathway underlies Alzheimer's disease. It is logical to assume that the gene products of the FAD genes are involved in this pathway, and we and other groups in this field of research have therefore focussed on the cell biology of these proteins.
Accumulating genetic evidence points to a major role for the product of the amyloid precursor protein gene on chromosome 21. This gene codes for the precursor of the proteinaceous components of the amyloid plaques, the hydrophobic 40-42 amino acid residues spanning amyloid ␤-peptides (A␤). All known clinical mutations cause either an increase in the production of these peptides or a shift towards the production of the longer form (containing 42 residues) which is prone to amyloidogenesis. An additional copy of the APP gene in the case of trisomy 21 (Down's syndrome) leads also to AD in these patients, further arguing for the important role of APP in the pathogenesis of AD. 1, 2 Point mutations that cause FAD were more recently identified in the presenilin-1 (PS1) gene on chromosome 14 and the presenilin-2 (PS2) gene on chromosome 1. 3 Since mutations in the presenilin-1 gene turned out to be the culprit in the majority of the familial forms of the disease, 3 it became important to delineate where exactly PS1 fits in the picture, ie in APP processing and plaque formation, in tangle formation, or in the neurodegeneration of the disease. Neither the Correspondence: P Saftig, Zentrum Biochemie und Molekulare Zellbiologie, Abteilung Biochemie II, Universitat Gottingen, Germany. E-mail: saftigȰuni-bc2.gwdg.de primary structure, 4 nor the subcellular localization 5 revealed what its biological or pathological role could be, although it became rapidly clear from studies in fibroblasts taken from FAD patients, and from studies in transgenic animals and transfected cell cultures, that PS1 mutations caused an increased production of the longer beta-amyloid peptide. 3, 6 This provides strong evidence for a direct link between the PS1 mutations and the generation of amyloid plaques and corroborated the idea that abnormal processing of APP is central to the pathogenesis of Alzheimer's disease. (Notice that this statement is more general than the classical 'amyloid hypothesis' which focusses mainly on amyloid plaque formation.)
The major problem to be addressed was how presenilin mutations could affect APP processing. We decided to take a genetic approach and generated mice in which the PS1 gene was deleted (PS1 knockout mice) to investigate the consequences for APP processing. 7 Unfortunately, PS1-knockout (PS1−/−) mice die late in embryogenesis. The embryos displayed a severe growth retardation with skeletal malformations that are most pronounced in the caudal regions. Cranial and intraventricular and intraparenchymal bleeding in the brain was observed in most of the PS1(−/−) embryos. 8, 9 Interestingly, immunohistological analyses showed a marked reduction in the density of cerebral vascularisation and a dense packaging of cells in the cortical plate. The delineation of the internal laminar and the normal radial organisation of the neurons was greatly disturbed (Dieter Hartmann PS and BDS, unpublished observations). The fatal developmental defect resembles the phenotype seen in other mice in which the Notch gene is deleted. Evidence was presented that deficient Notch signaling could also underly the phenotype of the PS1−/− mice. 9 While these observations clearly point to an important role for PS1 during embryonic development, the question of what role PS1 played in APP processing and eventually in Alzheimer's disease remained unanswered.
We decided therefore to circumvent the problem of embryonic lethality of the PS1−/− embryos, by generat-ing primary cultures of neurons of E14 littermate embryos, removed by caesarian section at a moment when the animals are still alive and their brains are already relatively well developed. 7 To our satisfaction, the neuronal cultures turned out to be vital and no gross differences in the phenotype of the cultures derived from PS1+/+ or PS1−/− littermates were observed. In a next step, and using published methodology, 10, 11 we analyzed the proteolytic processing of endogenous mouse and transected human APP. Recombinant Semliki Forest Virus was used to express human APP, which we considered to be important because we had found before that mouse APP compared to human APP yields much less amyloid peptide on a per mole basis 10 (this is probably one of the reasons why rodents do not develop naturally Alzheimer's disease). In doing so we found two striking effects on APP processing in the PS1(−/−) culture: about 80% less amyloid-␤ peptide was secreted and membrane-associated carboxyterminal APP fragments containing the amyloid-beta peptide accumulated. Interestingly, the production of both the short (40 amino acid residues) and the long form (42 amino acid residues) of the amyloid-␤-peptides was equally decreased. 7 What do these results mean? They clearly point out that PS1 has a specific effect on one selective step in the proteolytic processing of APP, ie the gamma-secretase cleavage in the transmembrane domain. This cleavage is the final one to release the amyloid peptide from APP. The results also support the idea that the clinical mutations in the presenilins cause a gain of function. However, this gain of function is selective, since, in contrast to the deletion of PS1, the PS1 point mutations affect only the production of the longer amyloid peptide form. 6 While one could be tempted to conclude that PS1 is actually the gamma-secretase, two facts contradict this assumption. First, no structural or sequence homology between PS1 and any protease domain known so far is found. Second, since some amyloid peptide secretion (both 1-40 and 1-42) persists, one has to conclude that residual gamma-secretase activity remains present in the PS1−/− neurons. We therefore concluded that PS1 is only indirectly involved in the gamma-secretasecleavage, ie as a cofactor or facilitator of this process. The term 'cofactor or facilitator' function of PS1 in the gamma-secretase cleavage remains sufficiently vague to cover two possibilities. The first is that PS1 is needed for the transport of the APP carboxyterminal fragments to a subcellular compartment in which the gamma-secretase resides. While this interpretation raises more questions that it answers, some support comes from studies on a homologue of PS1 in C. elegans, suggesting a role in vesicle formation and protein trafficking. 12 The second interpretation that PS1 constitutes a direct molecular link between APP-carboxyterminal fragments and gamma-secretase is, at least in our opinion, more attractive. An exciting analogy from studies on the regulation of the cholesterol metabolism by the transcription factor, sterol regulatory element binding protein-(SREBP) 13 has inspired this idea. The cleavage of the membrane-bound transcription factor SREBP depends on the presence of a SREBP-cleavage activating protein (SCAP) which resides, similar to PS1, in the endoplasmic reticulum. SCAP is a multimembrane spanning protein, and is needed for the proper processing of SREBP, although another multimembrane spanning enzyme, the S2P-metalloproteinase, is in fact responsible for the actual cleavage.
14 A similar scheme could apply to APP cleavage (Figure 1a) . 13 While our work has fitted two pieces in the complex puzzle of Alzheimer's disease, many questions remain unanswered. It is for instance unclear to us why the FAD-causing mutations in PS1, in contrast to the deletion mutation of PS1, selectively affect the production of the amyloid 42 peptide. One possibility is that the mutations cause a slight shift in the way APP is presented to the gamma-secretase by PS1. A second question is in what subcellular compartment gammasecretase is residing. Since Presenilin 1 is mainly present in the endoplasmic reticulum, one would expect the same localization for gamma-secretase. Our data indicate however that APP is first processed by the alpha-and beta-secretases which are active in the Golgi apparatus, the cell surface and endosomes, and only then by the gamma-secretase controlled by PS1. Some recycling of APP carboxyterminal fragments to the endoplasmic reticulum must therefore occur if we maintain the idea of a direct interaction between PS1 and these fragments. This is from a fundamental cell biological point of view not easy to understand. An alternative hypothesis, which merges to a certain degree all the previous ones, is that PS1 controls the transport of gamma-secretase(s) from the endoplasmic reticulum towards a subcellular compartment further downstream in the biosynthetic pathway, a compartment to which also APP carboxyterminal fragments could recycle (Figure 1b) .
Regardless of these interpretations, our results clearly demonstrate 7 that inactivation of PS1 decreases amyloid ␤-peptide production. This raises the hope that inhibition of PS1 function could stop the progressive accumulation of the amyloid plaques in the brains of Alzheimer's disease patients. Two important caveats have to be mentioned however. First, it is unclear whether inhibition of the PS1 function in the adult brain is similarly deleterious as it is found to be in the developing embryo. Second, inhibition of PS1 function not only decreases amyloid peptide generation, but also increases production of APP carboxyterminal fragments. Such carboxyterminal fragments could have neurotoxic effects of their own. 15 In conclusion, while we were able to establish the link between APP and PS1 protein, many new questions were also raised. The major goal now is to identify (the) gammasecretase(s) which will be the direct way to solve these new questions. 
